Halozyme Therapeutics (HALO) Amortization - Intangibles (2022 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Amortization - Intangibles of $29.5 million for Q1 2026, up 66.15% year-over-year from $17.8 million in Q1 2025, and up 26.25% quarter-over-quarter from $23.4 million in Q4 2025.
Halozyme Therapeutics (HALO) Amortization - Intangibles (2022 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Amortization - Intangibles for 5 consecutive years, with $29.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization - Intangibles rose 66.15% year-over-year to $29.5 million; the TTM figure through Mar 2026 stood at $88.4 million (up 24.44% YoY), while the FY2025 annual figure was $76.7 million, up 7.9% from the prior year.
- Amortization - Intangibles climbed to $29.5 million in Q1 2026 per HALO's latest filing, from $23.4 million in the prior quarter.
- Across five years, Amortization - Intangibles topped out at $29.5 million in Q1 2026 and bottomed at $4.6 million in Q4 2022.
- Historically, Amortization - Intangibles has averaged $18.4 million across 5 years, with a median of $17.8 million in 2023.
- On a YoY basis, Amortization - Intangibles climbed as much as 290.2% in 2023 and fell as far as 25.2% in 2023.
- Halozyme Therapeutics' Amortization - Intangibles stood at $4.6 million in 2022, then soared by 290.2% to $17.8 million in 2023, then changed by 0.0% to $17.8 million in 2024, then jumped by 31.61% to $23.4 million in 2025, then grew by 26.25% to $29.5 million in 2026.
- Business Quant data shows HALO's Amortization - Intangibles at $29.5 million in Q1 2026, $23.4 million in Q4 2025, and $17.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.51 Mn |
| Mar 31, 2026 | 29.51 Mn |
| Dec 31, 2025 | 23.38 Mn |
| Sep 30, 2025 | 17.76 Mn |
| Jun 30, 2025 | 17.76 Mn |
| Mar 31, 2025 | 17.76 Mn |
| Dec 31, 2024 | 17.76 Mn |
| Sep 30, 2024 | 17.76 Mn |
| Jun 30, 2024 | 17.76 Mn |
| Mar 31, 2024 | 17.76 Mn |
| Dec 31, 2023 | 17.76 Mn |
| Sep 30, 2023 | 20.34 Mn |
| Jun 30, 2023 | 17.84 Mn |
| Mar 31, 2023 | 17.84 Mn |
| Dec 31, 2022 | 4.55 Mn |
| Sep 30, 2022 | 27.19 Mn |
| Jun 30, 2022 | 11.40 Mn |